These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 23706692)

  • 1. Treatment of prostate and renal cancer with oral drugs (abiratarone and antiangiogenic agents): positioning statement from the Spanish Association of Urology.
    Villavicencio H; Hernández C; Gómez A; Cózar JM; Rodríguez-Antolín A; Prieto L; de Cabo M; Malet JM; Extramiana J; Mata J; Arrabal M; Server G; Solsona E; Del Valle JI; Miguélez E; Gutiérrez E; Elizalde A; Mateos J; Artiles JL; Jiménez-Cidre M; Nalda LM; Cruz N; Ozonas M; Caffaratti J; Esteban M; Unda M; Reina C; Alvarez-Ossorio JL; Lledó E; Angulo JC
    Actas Urol Esp; 2013 Jun; 37(6):321-3. PubMed ID: 23706692
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
    Colomer R; Alba E; González-Martin A; Paz-Ares L; Martín M; Llombart A; Rodríguez Lescure Á; Salvador J; Albanell J; Isla D; Lomas M; Rodríguez CA; Trigo JM; Germà JR; Bellmunt J; Tabernero J; Rosell R; Aranda E; Cubedo R; Baselga J;
    Ann Oncol; 2010 Feb; 21(2):195-198. PubMed ID: 20110291
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of thyroid cancer with the new oral agents.
    Galofré JC; Gómez-Sáez JM; Escola CA; Anda E; Calleja A; Donnay S; Lucas-Martin A; Menéndez-Torre E; Pereg V; Pérez-Corral B; Santamaría J; Riesco-Eizaguirre G; Zafon C;
    Ann Oncol; 2011 Oct; 22(10):2343. PubMed ID: 21859897
    [No Abstract]   [Full Text] [Related]  

  • 4. Positioning statement of the Spanish Association of Urology on the document published by the Spanish Society of Medical Oncology about the use of medical treatments in oncological patients.
    Esteban Fuertes M; Gómez Rodríguez A; Cortiñas González JR; Prieto Chaparro L; Chantada Abal V; Cozar Olmo JM; Juarez Soto A; Alvarez-Ossorio Fernández JL;
    Actas Urol Esp; 2017 Sep; 41(7):413-415. PubMed ID: 28847367
    [No Abstract]   [Full Text] [Related]  

  • 5. Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.
    Salvador J; Aparicio J; Baron FJ; Garcia-Campelo R; Garcia-Carbonero R; Lianes P; Llombart A; Isla D; Piera JM; Munoz M; Puente J; Rivera F; Rodriguez CA; Virizuela JA; Martin M; Garrido P
    Clin Transl Oncol; 2017 Mar; 19(3):341-356. PubMed ID: 27562312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erythropoiesis-stimulating agents in cancer patients: ESMO recommendations for use.
    Scrijvers D; Roila F;
    Ann Oncol; 2009 May; 20 Suppl 4():159-61. PubMed ID: 19454443
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted drugs take centre stage at US cancer meeting.
    McCarthy M
    Lancet; 2001 May; 357(9268):1593. PubMed ID: 11377652
    [No Abstract]   [Full Text] [Related]  

  • 8. MASCC Oral Agent Teaching Tool (MOATT): yesterday, today and tomorrow.
    Lemonde M
    Can Oncol Nurs J; 2014; 24(3):207-10. PubMed ID: 25189059
    [No Abstract]   [Full Text] [Related]  

  • 9. European Association of Urology position statement on screening for prostate cancer.
    Abrahamsson PA; Artibani W; Chapple CR; Wirth M
    Eur Urol; 2009 Aug; 56(2):270-1. PubMed ID: 19481336
    [No Abstract]   [Full Text] [Related]  

  • 10. Primary colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
    Van Cutsem E; Oliveira J;
    Ann Oncol; 2009 May; 20 Suppl 4():49-50. PubMed ID: 19454461
    [No Abstract]   [Full Text] [Related]  

  • 11. Cancer, fertility and pregnancy: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Pentheroudakis G; Pavlidis N; Castiglione M;
    Ann Oncol; 2009 May; 20 Suppl 4():178-81. PubMed ID: 19454448
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of oral and gastrointestinal mucositis: ESMO clinical recommendations.
    Peterson DE; Bensadoun RJ; Roila F;
    Ann Oncol; 2009 May; 20 Suppl 4():174-7. PubMed ID: 19454447
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy-induced nausea and vomiting: ESMO clinical recommendations for prophylaxis.
    Herrstedt J; Roila F;
    Ann Oncol; 2009 May; 20 Suppl 4():156-8. PubMed ID: 19454442
    [No Abstract]   [Full Text] [Related]  

  • 14. Management of febrile neutropenia: ESMO clinical recommendations.
    Marti FM; Cullen MH; Roila F;
    Ann Oncol; 2009 May; 20 Suppl 4():166-9. PubMed ID: 19454445
    [No Abstract]   [Full Text] [Related]  

  • 15. American Society of Clinical Oncology statement regarding the use of outside services to prepare or administer chemotherapy drugs.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 May; 21(9):1882-3. PubMed ID: 12668649
    [No Abstract]   [Full Text] [Related]  

  • 16. Prostate cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Horwich A; Parker C; Kataja V;
    Ann Oncol; 2009 May; 20 Suppl 4():76-8. PubMed ID: 19454471
    [No Abstract]   [Full Text] [Related]  

  • 17. [Overview on the behalf of the Society for Arterial Infusion Chemotherapy Research].
    Taguchi T
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):919-22. PubMed ID: 2730031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of the Spanish Association of Urology National Registry in Active Surveillance for prostate cancer.
    Rubio-Briones J; Borque A; Esteban LM; Iborra I; López PA; Gil JM; Pallás Y; Fumadó L; Martínez-Breijo S; Chantada V; Gómez E; Quicios C; Congregado CB; Medina R; Ortiz M; Montesino M; Clar F; Soto J; Campá JM
    Actas Urol Esp; 2016; 40(1):3-10. PubMed ID: 26115777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma.
    Bex A; Albiges L; Ljungberg B; Bensalah K; Dabestani S; Giles RH; Hofmann F; Hora M; Kuczyk MA; Lam TB; Marconi L; Merseburger AS; Staehler M; Volpe A; Powles T
    Eur Urol; 2017 May; 71(5):719-722. PubMed ID: 27986369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.